

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/601997

INTERNATIONAL APPLICATION NO

ATTORNEY'S DOCKET NUMBER  
14-020210US17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$760.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS** PTO USE ONLY

\$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	61 - 20 =	41	X \$18.00
Independent claims	10 - 3 =	7	X \$78.00

\$ 738

\$ 546

MULTIPLE DEPENDENT CLAIM(S) (if applicable)

+ \$260.00

\$ 260

**TOTAL OF ABOVE CALCULATIONS =**

\$ 2384

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$ 1192

**SUBTOTAL =**

\$ 1192

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$ 1192

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

\$

80

**TOTAL FEES ENCLOSED =**

\$ 1272

Amount to be:

refunded

\$

charged

\$

1272

a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 50-0893 in the amount of \$ 1272 to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 50-0893. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jonathan Alan Quine  
LAW OFFICES OF JONATHAN ALAN QUINE  
P.O. BOX 458  
Alameda, CA 94501  
United States of America

*Jonathan Alan Quine*

SIGNATURE:

Jonathan Alan Quine

NAME

41,261

REGISTRATION NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

14-020210US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/601997

INTERNATIONAL APPLICATION NO.  
PCT/US98/27942INTERNATIONAL FILING DATE  
18 December 1998 (18.12.98)PRIORITY DATE CLAIMED  
19 December 1997 (19.12.97)

TITLE OF INVENTION NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC ACIDS

APPLICANT(S) FOR DO/EO/US James G. Keck, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.  
2 assignment documents with cover sheets are included for recordation.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - 1) Petition for Revival of an International Application, including Statement
  - 2) International Preliminary Examination Report
  - 3) International Written Opinion
  - 4) Response to the Written Opinion filed March 8, 2000 (Please note the amendments requested in this response were not entered or considered in the International Preliminary Examination report)
  - 5) Powers of Attorney executed for the International Application
  - 6) Verified Statement of Small Entity Status
  - 7) Certificate of Mailing and Receipt Acknowledgement Postcard

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) & 1.27(c)) - SMALL BUSINESS CONCERN**

Applicant or Patentee: James G. Keck, Jocelyn M. Molony, and Sophia S. KuoApplication or Patent No.: (not yet known)

Filed or Issued: (submitted herewith)

Title: NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC ACIDS

I hereby declare that I am:



the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: GeneTrace Systems, Inc.Address of Small Business Concern: 1401 Harbor Bay Parkway, Alameda, CA 94502

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC ACIDS** by inventor(s): **James G. Keck, Jocelyn M. Molony, and Sophia S. Kuo** described in:



the specification filed herewith.

Application No.   , filed   .Patent No.   , issued   .

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)


Name  
Address
☐ Individual    ☐ Small Business Concern    ☐ Nonprofit Organization
Name  
Address
☐ Individual    ☐ Small Business Concern    ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: GEORGE LaMOTTETitle of Person if Other than Owner: CHIEF EXECUTIVE OFFICERAddress of Person Signing: 1401 Harbor Bay Parkway, Alameda, CA 94502

Signature



Date

7/15/10

**NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC  
ACIDS**

5

**INTRODUCTION**

**Technical Field**

The present invention is related to methods and compositions for the high-throughput delivery and non-bacterial amplification of a nucleic acid of unknown function or  
10 oligonucleotides related to a nucleic acid of unknown function for identifying new genes or gene functions that are involved in specific cell phenotypes using catalytic RNA.

**Background**

Many disease states are characterized by abnormal production or function of gene  
15 products such as proteins. The abnormality may be due to a defective gene, overproduction of a protein by a normal gene or improper temporal expression. Such abnormal or excessive production of protein can have direct effects on cells within the body or can initiate a cascade of events involving other proteins within the body, thereby producing undesirable effects. However, in many cases the disease-related gene is as yet unidentified.

20 Databases containing several million sequences of genes, gene fragments, and essential sequence tags (ESTs) have been developed and are continuously expanding; however, more economical and efficient methods are needed to determine the function(s) of the products encoded by these sequences and their role in disease or the expression of a given phenotype. Different approaches have been used to elucidate the function of an individual  
25 gene, including biochemical approaches, reverse genetics, genome characterization and sequencing, inactivation of gene function, gene expression and mutational analysis. Gene function can be inactivated at the DNA level by homologous recombination, by triplex technology in which triplex structures are formed which interfere with transcription of DNA into mRNA, by antibodies at the protein level or by antisense nucleic acids and ribozymes at  
30 the RNA level.

The development of transgenic techniques, in which a gene of interest has been inserted or deleted in a host cell, has been an important advance in the tools available for studying the function of genes at the organismal level. In particular, since the advent of

automated DNA synthesis, oligonucleotides have been increasingly employed to analyze genes and their functions. Oligonucleotides expressed intracellularly in the form of polypeptides, antisense RNA and ribozymes have been used to alter gene expression as a method of determining and assigning gene function. However, these genetic approaches to elucidate gene function(s), as currently employed, share a common limitation, namely the need to identify, clone and sequence the gene of interest; the currently used techniques involve several bacterial or bacteriophage cloning and subcloning steps for the isolation, sequencing and manipulation of the gene of interest. This is a significant limitation, in terms of both time and expense. The requirement for multiple bacterial or bacteriophage cloning steps thus has rendered genetic techniques impractical for high-throughput screening assays for routine genetic analysis.

It therefore is of interest to develop a high-throughput system that avoids bacterial cloning for the delivery, expression and amplification of DNA and RNA that can be used to identify the function of a product encoded by a nucleic acid.

#### **Relevant literature**

An RNA molecule not naturally occurring in nature having enzymatic activity independent of any protein is disclosed in USPN 4,987,071. General rules for the design of hammerhead ribozymes that cleave target RNA in *trans* are described in Haseloff and Gerlach (1988) *Nature* 334:585-591. Miniribozymes are disclosed in Uhlenbeck, (1987 *Nature* 328:596-603. Methods for optimizing cleavage of a target RNA by a ribozyme are described in USPN 5,496,698. Reporter gene suppression by engineered hammerhead ribozymes in mammalian cells is described in Cameron and Jennings, (1989) *Proc. Natl. Acad. Sci. (USA)* 86:9139-9143. Ribozyme expression from a retroviral vector is described in Sullenger and Cech, (1993) *Science* 262:1566-1569. The expression of hammerhead ribozymes operatively linked to a T7 promoter is described in Chowrira *et al.* (1994) *J. Biol. Chem.* 269:25856-25864. Co-localizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors is described in Sullenger, (1995) *Appl. Biochem. Biotechnol.* 54:57-61. Screening of retroviral cDNA expression libraries is described in Kitamura *et al.*, (1995) *Proc. Nat. Acad. Sci. (USA)* 92:9146. Selection of efficient cleave sites in target RNAs by using a ribozyme expression library is described in Lieber and Strauss, (1996) *Mol. Cell. Biol.* 15:540-551. Approaches for the identification and cloning of differentially expressed genes is discussed in Soares, (1997) *Curr. Opin. Biotechnol.* 8:542-546. The development of high-

throughput screen is discussed in Jayawickreme and Kost, (1997) *Curr. Opin. Biotechnol.* 8:629-634. The high-throughput screen for rarely transcribed differentially expressed genes is described in von Stein *et al.*, (1997) *Nucleic Acids Res.* 25:2598-2602. High-throughput genotyping is disclosed in Hall, *et al.* (1996) *Genome Res* 6:781-790. The design of antisense RNA is disclosed in Sczakiel, (1997) *Antisense Nucleic Acid Drug Dev.* 7:439-444. Antisense mRNA regulation of gene expression is disclosed in USPN 5,457,281 USPN 5,190,931, and USPN 5,2720,65.

### SUMMARY OF THE INVENTION

Methods, and compositions for use therein, are provided for determining the function of a sample nucleic acid of unknown function, in which a non-bacterial cloning system is used for amplification of an oligonucleotide family which is related to the sample nucleic acid. The non-bacterial amplification method includes the steps of digesting an expression plasmid with two or more restriction enzymes so that the resulting digested expression vector is prevented from self-annealing and to provide directionality for the subsequent cloning of the nucleic acid-to-be-expressed which can be the sample nucleic acid or a related nucleic acid; simultaneously ligating in a matrix format the nucleic acid-to-be-expressed to the digested expression vector, so that one or more of the nucleic acids-to-be-expressed is operatively linked to transcriptional control elements in the digested expression vector; simultaneously introducing in a matrix format into a cell culture that contains one or more host cell(s) that express(es) a target nucleic acid(s) that contains the nucleotide sequence of the sample nucleic acid; and growing the cell culture so that the one or more of the nucleic acids-to-be-expressed are amplified and transcribed. The transcription product of the nucleic acid-to-be expressed is antisense RNA, ribozymes or mRNA that is translated into a polypeptide or a fusion polypeptide, expression of which is designed to alter the phenotype of the host cell. To identify and assign a function to the sample nucleotide sequence, the transfected or infected cell culture is analyzed for phenotypic changes produced as a result of the intracellular amplification and transcription of the expressed nucleic acid.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C show a family of oligonucleotides which encode ribozymes targeting the mRNA of green fluorescent protein (EGFP). The family of oligonucleotides was developed by identifying ribozyme consensus cleavage sites throughout the mRNA which are

used as the basis for synthesizing DNA coding sequence of the complementary ribozyme sequences shown as the upper sequences in Figures 1A-1C (SEQ ID NOS:1-20). The lower sequences in Figures 1A-1C are the complementary sequences which are annealed to the ribozyme coding sequence to form double-stranded DNA for introduction into a host cell.

5 Figure 2 shows the sequences of delivery vectors containing incorporated oligonucleotides. A. shows the sequence of the insert region of pGEM-Sca/Pvu, (SEQ ID NO:38), obtained by sequence analysis and the predicted sequence of pGEM-oligo 1/3, (SEQ ID NO:39). Underlines represent the mutated sequences that were incorporated into the ribozyme vector. B. shows the sequence obtained for both pGEMEX-Sma/Kpn, (SEQ ID  
10 NO:40), and pGEMEX-oligo 2/3, (SEQ ID NO:41). Both strands of each ribozyme vector were sequenced. Underlines represent the mutated sequences that were incorporated into the ribozyme vector. Bold nucleotides represent the sequence original double-stranded oligonucleotide that was inserted into the vector.

Figure 3 shows sequences of clones (pGEMEX-oligo2) containing an inserted  
15 oligonucleotide, (SEQ ID NO:42), compared with the sequence obtained from the parental plasmid, (SEQ ID NO:43). Bold nucleotides represent the sequence that is complementary to the sequence of the single-stranded oligonucleotide.

Figure 4 shows sequences of clones (pGEMEX-oligo1/5/6) containing an inserted  
oligonucleotide, (SEQ ID NOS:44-45), compared with the sequence obtained from the  
20 parental plasmid, (SEQ ID NO:46). Bold nucleotides represent the one full length strand formed from the triple-stranded oligonucleotide.

#### **BRIEF DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The present invention uses high-throughput assembly, delivery, amplification and  
25 expression of one or more nucleic acids from a plasmid or viral vector in a host cell culture which includes at least one host cell and can contain a plurality of host cells, as a means of assigning a function to a product of the host cell. The amplification of the expressed nucleic acids is performed in the host cell and does not require bacterial or bacteriophage cloning prior its introduction into the host cells. The nucleic acids-to-be-expressed are related to a  
30 sample nucleic acid of unknown function and code an antisense RNA, a ribozyme, a polypeptide or a fusion polypeptide and include synthetic oligonucleotides, genomic DNA, cDNA, ESTs or fusion cDNA-ESTs. The sample nucleic acid is contained within the host cell by a target nucleic acid that codes for a product whose function is being assigned. The

expression of the nucleic acid in the host cell alters the host cell's phenotype, thereby, assigning function to the product coded by the target nucleic acid. The term "function" is intended to mean a detectable or measurable event. The term "phenotype" is intended to mean a characteristic of a specific cell or cell population. Synthetic oligonucleotides are designed by analyzing the nucleotide sequence of the sample nucleic acid of unknown function and can be designed to encode either a polypeptide, a fusion polypeptide, an antisense RNA or a ribozyme. Similarly, the sense or antisense strand of the genomic DNA, cDNA or EST can be expressed. The nucleic acid-to-be-expressed is related to a sample nucleic acid sequence of unknown function which can be genomic DNA, cDNA, EST or RNA or a nucleotide sequence derived or obtainable from any of the above.

By "polypeptide" is intended a molecule containing two or more amino acids joined by peptide bonds. By "fusion polypeptide" is intended a polypeptide attached to a label or tag. By "antisense RNA" is intended an RNA molecule that binds to a target nucleic acid molecule, thereby, inhibiting its function and the expression of the encoded product. By "ribozyme" is intended an RNA molecule that acts as an enzyme and has been engineered to cleave other RNA molecules; after binding selectively to its specific RNA target, it acts catalytically to cut, or cleave, the target RNA molecule.

The nucleic acids-to-be-expressed are introduced into any of a variety of vectors, depending on the availability of restriction enzyme sites, intracellular location, and transcriptional regulatory elements for delivery and expression of the nucleic acid in the target host cell. When the nucleic acids-to-be-expressed are oligonucleotides, they can be simultaneously synthesized on solid supports in a matrix format, and simultaneously deprotected and cleaved. If complementary pairs of oligonucleotides are simultaneously synthesized, deprotected and cleaved in a matrix format, they can be simultaneously annealed and ligated to a vector. Alternatively, a single oligonucleotide is annealed to the delivery vector, ligated and the complementary strand can be filled in by a DNA polymerase or the complementary strand can be filled in before ligation. Three oligonucleotides can be annealed together with the delivery vector; intervening gaps are filled in by a DNA polymerase and ligated with a DNA ligase. The delivery vector containing the nucleic acid-to-be-expressed optionally is treated to increase the supercoiling of the delivery vector DNA, for example using DNA gyrase so as to improve uptake of the DNA into a recipient cell, such as a packaging cell or the intended target host cell. From one to multiple nucleic acids in a chosen delivery vector are introduced into the recipient cell. When a retrovirus vector is



used, following preparation of recombinant retrovirus in a packaging cell, the recombinant retrovirus is used to infect a host cell containing the target nucleic acid. Instead of using a viral vector to make a virus for infection, a plasmid expression vector can be transfected directly into a host cell containing the nucleic acid of interest. The infected or transfected host cell is grown and the phenotype of the infected or transfected host cell is analyzed to determine any alterations in phenotype as compared to an uninfected or untransfected host cell. Alterations in cell phenotype are then correlated with the target nucleic acid so as to assign a function to a product coded for by the sample nucleic acid.

There are several advantages to the subject invention. The ability to eliminate the amplification step of plasmid DNA in bacteria such as *E. coli* is a major cost saving step as well as a time saving step over existing technologies: *E. coli* amplification can add several days onto the entire process. The subject process lends itself to automation when implemented in a 96-well or similar multi-well or matrix format. In addition, the expression of polypeptides, fusion polypeptides, antisense RNA and ribozymes of the disclosed invention offer several advantages over currently available techniques. High-throughput delivery and expression of these molecules from a gene vector family offers the advantage that multiple members of these molecules can be introduced into and expressed in host cell cultures to enable identification of genes by a manageable screening process. The number of polypeptides, fusion polypeptides, antisense RNA or ribozymes expressed per cell depends on the multiplicity of infection for a virus vector or the amount of DNA transfected per cell for a plasmid vector. The high-throughput delivery permits the screening of a large number of nucleic acid constructs in a relatively short period of time. Furthermore, the construction of the polypeptides, fusion polypeptides, antisense RNA and ribozymes with synthetic oligonucleotide DNA offers the additional advantage that directionality is conveniently achieved by incorporating unique restriction enzyme sites at both ends of each of the oligonucleotides used to prepare the double-stranded DNA coding for these molecules so that double-stranded DNA is ligated to the delivery vector in the correct orientation for expression. If the same restriction enzyme sites, blunt ends or restriction enzyme sites comprising compatible cohesive ends are used for the ligation, theoretically about 50% of all the constructs would be expressed in the incorrect orientation.

Other advantages of the subject invention include the capability to regulate the magnitude and timing of nucleic acid expression and high-throughput delivery. Operatively linking the nucleic acids-to-be-expressed to a regulatable promoter provides temporal and/or

cell type specific control throughout the screening assay. Additionally, the magnitude of expression can be modulated using promoters that differ in their transcriptional activity.

Ribozyme technology in particular offers several advantages over other methods used to determine which genes are relevant to a disease because they are selective for a specific target genetic sequence and act catalytically (Koizumi *et al.*, (1989) *Nuc. Acids Res.* 17:7059-7071; Bennett *et al.*, (1992) *Nuc. Acids Res.* 20:831-837). These properties can be used to identify the role of a target genetic sequence and to characterize its cellular function. In the disclosed invention, it is not necessary to develop conformational models of the target nucleic acids to identify regions which are particularly accessible. Such models typically are developed using computer-assisted predictions of possible thermodynamically stable secondary structures. The need for such models is avoided by creating a family of complementary ribozyme nucleotide sequences which are distributed throughout a target nucleic acid sequence.

Ribozymes can be designed to target any length nucleotide sequence from a full-length gene to a short EST sequence. Generally, a family of between 3 and 20 ribozymes is designed for each sample nucleotide sequence of interest to increase the probability that cleavage of the mRNA encoded by the nucleotide sequence of interest occurs in the host cell. The ribozyme includes two stretches of antisense oligonucleotides, each generally 6 to 8 nucleotides (nt) long, to bind to the mRNA, with the sequence forming the catalytic domain or catalytic core in between. The bases immediately adjacent to either side of the catalytic core in the sense strands constitute the ribozyme binding sequence when expressed as RNA that is complementary to a mRNA sequence. The mRNA sequence contains a consensus cleavage site for the ribozyme, such as NUN (N=any nucleotide) (Kashani-Sabet and Scanlon, (1995) *Cancer Gene Therapy* 2:213-223; Perriman *et al.*, (1992) *Gene (Amst.)* 113:157-163; Ruffner *et al.*, (1990) *Biochemistry* 29:10695-10702; Birikh *et al.*, (1997) *Eur. J. Biochem.* 245:1-16; Perrealt *et al.*, (1991) *Biochemistry* 30:4020-4025) if the catalytic domain is derived from a hammerhead ribozyme, or the triplet GUC if the catalytic domain is derived from a hairpin ribozyme. Generally, the entire ribozyme binding sequence is about 12 to 30 nucleotides in length. The catalytic region generally is greater than about 22 nucleotides in length or can be shorter. The catalytic region of miniribozymes is generally about 7 nucleotides in length (Uhlenbeck *et al.* *Nature* 328:596-603).

Oligonucleotide DNA can be designed to express antisense RNAs or functional mRNAs that encode a polypeptide or fusion polypeptide. The strand coding the antisense

RNA or the open reading frame of the polypeptide or fusion polypeptide and the complementary strand are prepared individually and annealed to form double-stranded DNA which may include a means for determining directionality of expression. The double-stranded DNA is formed either by annealing two complementary oligonucleotides to form a double-stranded oligonucleotide or by annealing three oligonucleotides to form a triple-stranded oligonucleotide that contains single-stranded gaps and single stranded ends that are complementary to the ends of a delivery vector. Single-stranded portions of the oligonucleotide/vector can be filled in by treatment with a DNA polymerase such as Klenow, Taq polymerase or a cellular polymerase. Single-stranded ends of the triple-stranded oligonucleotide contain excess nucleotides that may be of any length but are preferably between two and ten nucleotides and most preferably between three and five nucleotides. Alternatively, a single-stranded oligonucleotides can be designed that either encode a transcription product that is a ribozyme or are complementary to a strand that encodes a transcription product that is a ribozyme. One end of the single-stranded oligonucleotide is complementary to an end of a linearized delivery vector. The strand that is complementary to the single-stranded oligonucleotide is formed with a DNA polymerase such as a cellular polymerase, Klenow or Taq polymerase. Insertion of such double- or single-stranded oligonucleotides into a delivery vector forms the ensuing ribozyme vector. Site-directed mutagenesis is employed to alter the ribozyme coding sequence to optimize cleavage by the ribozyme of a particular substrate, change substrate specificity of the ribozymes or identify nucleotides that are important for substrate binding and catalysis. In addition, genomic DNA, cDNA or an EST can be directly expressed as a polypeptide, a fusion polypeptide or an antisense mRNA.

In the following examples, a ribozyme family is targeted to a reporter gene, green fluorescent protein (GFP), that is expressed in CHO-AA8 Tet-Off cells or can be expressed in 293 Tet-Off cells (Clontech, Palo Alto, CA). GFP from the firefly *Aequorea victoria* emits bright green light upon mere exposure to UV or blue light and unlike other bioluminescent reporters, does not require additional proteins, substrates, or cofactors to emit light. EGFP encodes a protein which has a single, red shifted spectrum and increased expression relative to GFP, and therefore, is easily monitored in living cells by fluorescence microscopy and fluorescence-activated cell sorting (FACS). Ribozyme activity is inversely proportional to reporter gene signal. Other reporter genes, for example chloramphenicol acetyltransferase (CAT), beta-galactosidase, or alkaline phosphatase, also can be used.

For annealing the complementary oligonucleotide DNA strands, special conditions are not required. For example, both strands can be dissolved in water then mixed at a one to one molar ratio. They can be mixed in almost any buffer system, T4 ligase buffer, Exonuclease 3 buffer, Mung Bean Nuclease buffer. No special heating is required, room temperature is adequate. This mixing and annealing of the oligonucleotide strands generally occurs in a 96-well microtiter dish although other appropriate apparatus also can be used.

The means for determining directionality of expression conveniently is the use of unique non-blunt end forming restriction enzyme sites at both ends of the oligonucleotide DNA, thus the two oligonucleotides to be annealed share complementary sequences except at the ends where they will be able to bind to a restriction enzyme site. For the restriction enzyme sites, any non-blunt end forming restriction enzyme site can be used at either end, depending on the sites within the DNA vector into which the oligonucleotide DNA fragment is to be ligated. Having different sites at each end gives directionality. Any restriction enzyme that produces unique non-blunt cohesive ends suitable for ligation by DNA ligase can be used, for example *Aat* II, *Eco*R I, *Bam*H I, *Hind* III, *Pst* I. If necessary, a restriction enzyme site with a cohesive end can be used with a restriction enzyme site that produces a blunt end. Alternatively, the two oligonucleotides can be completely complementary, including the ends and digested with restriction enzymes prior to ligation with the delivery vector. In this case, it is preferred that the restriction enzyme sites does not occur within the oligonucleotide DNA coding region, otherwise partial digestions will be required.

The delivery vector into which the nucleic acids-to-be-expressed are to be ligated is digested with the appropriate restriction enzymes, either simultaneously or sequentially, to produce the appropriate ends for directional cloning of the nucleic acid whether it be oligonucleotides, genomic DNA, cDNA, or a previously cloned DNA. The nucleic acids-to-be-expressed preferably contain compatible ends to facilitate ligation to the vector in the correct orientation. For the example of oligonucleotide ligation, the ends compatible to the vector can be designed into the oligonucleotides. When the nucleic acids-to-be-expressed are genomic DNA, cDNA, or a previously cloned DNA, the compatible ends can be formed by restriction enzyme digestion or the ligation of linkers to the DNA containing the appropriate restriction enzyme sites. Alternatively, the vector can be modified by the use of linkers. The restriction enzyme sites are chosen so that transcription of the nucleic acid from the vector produces a ribozyme or antisense RNA targeted to the mRNA of interest or a polypeptide or a fusion polypeptide. Restriction enzyme digestion is routinely performed using commercially

available reagents according to the manufacturer's recommendations and will vary according to the restriction enzymes chosen. Once digested, the vector and nucleic acids-to-be-expressed can be purified by gel electrophoresis, chromatography or phenol/chloroform extraction and ethanol precipitation. The optimal purification method depends on the size and type of the vector and nucleic acids. Both can be used without purification. Generally, the nucleic acids-to-be expressed contain 5'-phosphate groups and the vector is treated with alkaline phosphatase to promote nucleic acid-vector ligation and prevent vector-vector ligation. If the nucleic acids-to-be-expressed are synthetic oligonucleotides, 5'-phosphate groups are added by chemical or enzymatic means before annealing. For ligation, ratios of nucleic acids-to-be-expressed DNA to vector DNA range from approximately 4:1 to 6:1. The ligation reaction is performed using T4 DNA ligase or other enzyme that catalyzes double-stranded DNA ligation. Reaction temperature and time can vary from 15°C to room temperature and from 18 hours to 5 minutes, respectively.

Delivery vectors produced by any of the above-identified methods can be amplified by transfecting cells (prokaryotic or eukaryotic) with the ligation mixtures and selecting for cells that contain the recombinant vectors. The selection method can employ drug resistance markers, visual markers such as green fluorescent protein or other selectable markers. Subsequent amplification of cells followed by isolation of vector DNA results in the production of novel ribozyme vectors.

One method for expression of the nucleic acids employs recombinant retroviruses. These vectors generally include as operatively linked components, retroviral long terminal repeats, packaging sequences and cloning site(s) for insertion of heterologous sequences. Other operatively linked components may include a nonretroviral promoter/enhancer and a selectable marker gene. Examples of retrovirus expression vectors which can be used include DC-T5T (Sullenger *et al.* 1990. *Mol. Cell Biol.* 10:6512-65230), *kat* (Blood. 1994 83:43-50), BOSC (*Proc. Natl. Acad. Sci. (USA)* (1993) 90:8392-8396), pBabe (*Proc. Natl. Acad. Sci. (USA)* (1995) 92:9146-9150) and RetroXpress™ (Clontech, Palo Alto, CA).

In some instances, it is desirable to increase expression of the designed oligonucleotides utilizing other promoters and/or enhancers in place of the promoter and/or enhancers provided in the expression vector. These promoters in combination with enhancers can be constitutive or regulatable. Any promoter/enhancer system functional in the target cell can be used. (See for example, *Molecular Virology* pp. 176-177; Hofmann, *et al.* 1996. *Proc. Natl. Acad. Sci. (USA)* 93:5185-5190; Coffin and Varmus, 1996. *Retroviruses*. Cold Spring

Harbor Press, NY; Ausubel *et al.* 1994. Current Protocols in Molecular Biology. Greene Publishing Associates, Inc. & Wiley and Sons, Inc.). Examples include: CMV immediate-early promoter, SV40, thymidine kinase promoter, metallothionine promoter, and tetracycline operator (Hofman *et al.*, (1996) *Proc. Natl. Acad. Sci (USA)* 93:5185-5190).

- 5 To package the recombinant retrovirus vectors containing the nucleic acid-to-be-expressed, cells lines are used that provide in *trans* the gene functions deleted from the recombinant retrovirus vector such that the vector is replicated and packaged into virus particles. The genes expressed in *trans* encode viral structural proteins and enzymes for packaging the vector and carrying out essential functions required for the vector's expression
- 10 following infection of the target host cell. Packaging cell lines and retrovirus vector combinations that minimize homologous recombination between the vector and the genes expressed in *trans* are preferred to avoid the generation of replication competent retrovirus. Packaging systems that provide essential gene functions in *trans* from co-transfected expression vectors can be used and packaging systems that produce replication competent
- 15 retroviruses. Following packaging, the recombinant retrovirus is used to infect target cells of interest. The envelope proteins expressed should permit infection of the target cell by the recombinant retrovirus particle. Retrovirus packaging cell lines which can be used include BOSC23 (*Proc. Natl. Acad. Sci. (USA)* 90:8392-8396), PT67 (Miller and Miller. 1994. *J. Virol.* 68:8270-8276, Miller. 1996. *Proc. Natl. Acad. Sci. (USA)* 93:11407-11413), PA317
- 20 (*Mol. Cell Biol.* 6:2895 (1986)) and PG13.

Other methods to obtain recombinant retrovirus particles also may be used. For example, the nucleic acids-to-be-expressed are functionally linked to eukaryotic transcriptional elements and is flanked by a retroviral packaging signal and 5' and 3' LTRs. This entire retrovirus construct is functionally linked to the T7 RNA polymerase promoter

25 and T7 terminator. Also encoded by the vector but not within the retroviral construct is a gene functionally linked to a eukaryotic promoter that expresses a T7 RNA polymerase (T7pol) that contains a nuclear localization signal (T7pol-nls). Following transfection of this vector into a retroviral packaging cell, the T7-nls is expressed and localized in the nucleus where it transcribes recombinant retroviral genomes that are packaged by the retroviral genes

30 expressed by the packaging cell. Because of the high transcriptional activity of T7pol-nls, high titered recombinant retrovirus titers can be achieved. Similar vectors, utilizing other DNA-dependent RNA polymerases, such as, SP6 or T3 also can be used.

In addition to recombinant retrovirus systems, other viral packaging systems such as adenovirus-associated virus (AAV), adenovirus, Sindbis virus, Semliki Forest virus, Epstein Barr virus, herpes simplex virus, HIV, or vaccinia virus. Each of these systems has a different host range and can be used to infect cells that are refractory to retrovirus expression, i.e., non-dividing cells. In the Sindbis virus system (Invitrogen, San Diego, CA), the nucleic acids-to-be-expressed are ligated into the multiple cloning site of a Sindbis virus DNA vector, i.e., pSinRep5, operatively linked to the Sindbis subgenomic promoter and polyadenylation site; the nucleic acids-to-be-expressed replaces the Sindbis virus structural protein genes. pSinRep5 includes an SP6 RNA polymerase promoter for the *in vitro* synthesis of recombinant Sindbis virus genomes; a packaging signal for recombinant RNA packaging; and the Sindbis nonstructural polyprotein gene open reading frame. For the production of Sindbis virus particles, the recombinant Sindbis vector encoding the oligonucleotide DNA is linearized, transcribed into RNA and co-transfected into vertebrate (BHK-21, Vero) or invertebrate cells (*Drosophila*) with RNA transcribed from the helper vector, pDH-BB, that encodes the viral structural proteins. Following transfection, the recombinant Sindbis genomic RNA acts as a mRNA, is translated into the Sindbis virus polymerase, and expresses the encoded polypeptide, fusion polypeptide, antisense RNA or ribozyme from the subgenomic promoter and the structural proteins from the helper RNA. Because of Sindbis virus' host range, the recombinant Sindbis virus can be packaged and used to express the encoded polypeptide, fusion polypeptide, antisense RNA or ribozyme in mammalian, avian, reptilian, mosquito and *Drosophila* cells (see for example, Xong, C. *et al.* (1989) *Science* 243:1188-1191; Huang, H.V. *et al.* (1993) United States Patent Number 5,217,879; Hahn C.S. *et al.* (1992) *Proc. Natl. Acad. Sci. (USA)* 89:2679-2683; Huang, M. and Sommers, J. (1991) *J. Virol.* 65:5435-5439).

For expression in AAV, the nucleic acid is cloned into an AAV expression vector, such as ALAPSN, that contains a cloning site functionally linked to a Moloney leukemia virus promoter and flanked by AAV terminal repeats and a packaging signal. ALAPSN also comprises a neomycin resistance gene functionally linked to SV40 transcription control elements. Similar AAV vectors, such as CWRSP and CWRSP.N, with comparable features may also be used. To produce recombinant AAV particles, 293 cells are infected with adenovirus type 5; 4 hours later the infected cells are co-transfected with the ALAPSN plasmid-oligonucleotide DNA construct and an AAV helper plasmid, pAAV/Ad (Samulski *et al.*, (1989) *J. Virol.* 63:3822-3828). As recombinant AAV is produced, the 293 cells undergo

cytopathology, becoming spherical and lose their ability to adhere to a tissue culture surface. Following development of maximal cytopathology the supernatant is harvested and, if necessary, concentrated (Halbert *et al.* 1997. *J. Virol.* 71:5932-5941).

For vaccinia virus expression, a replication competent vaccinia virus can be used. The nucleic acids-to-be-expressed are operatively linked to a vaccinia virus promoter, for example, P11. In a preferred embodiment, vaccinia virus strain MVA is used because it expresses recombinant genes but contains a deletion that renders it replication incompetent in many mammalian cells. Therefore, the nucleic acids can be expressed in target host mammalian cells without the development of vaccinia virus induced cytopathology. The recombinant vaccinia virus strain MVA is produced by infecting chicken embryo fibroblasts (CEF) with vaccinia MVA and transfecting the transfer vector, pG01, into which has been ligated the ribozyme and a marker gene (beta galactosidase) functionally linked to a vaccinia promoter, such as P11, and flanked by the MVA genome sequences that flank the site of the MVA genomic deletion. The P11-ribozyme/beta-galactosidase construct is inserted into the MVA genome by homologous recombination. Recombinant viruses can be identified by *in situ* staining for beta-galactosidase expression with X-gal (Wyatt *et al.* (1995) *Virology* 210:202-205).

The nucleic acids can also be expressed from plasmid expression vectors that are transfected directly into mammalian cells. The direct delivery of the plasmid expression vector into the mammalian cell without an intervening bacterial cloning or transformation step provides a significant savings in time and expense and increases the number of sample nucleic acids that can be studied. Expression plasmids containing cloning sites operatively linked to either SV40, CMV, metallothionine, or tetracycline transcriptional regulatory elements can be used: pCEP4 (Invitrogen, San Diego, CA), pCMV $\beta$ , (Clontech, Palo Alto, CA), pAlter<sup>®</sup>-MAX (Promega, Madison, WI). The plasmid preferably contains sequences to provide high-copy episomal replication and selectable markers for stable maintenance of the vector in the host cell. The plasmids containing the nucleic acids-to-be-expressed are transfected directly into the target cell of interest. In a preferred embodiment, the plasmids are supercoiled with a gyrase to increase transfection efficiency. In another embodiment, the nucleic acids-to-be-expressed are ligated into plasmids and functionally linked to the T7, SP6, T3 or a similar RNA polymerase promoter. The plasmid expression vectors that can be used include: pGEM-3Z, pAlter<sup>®</sup>-Ex1 (Promega, Madison, WI). The plasmid-nucleic acids-to-be-expressed construct is transfected into mammalian cells that are infected with vaccinia strain



MVA that expresses the appropriate RNA polymerase (Wyatt *et al.*, (1995) *Virology* 210:202-205). For the example of vaccinia MVA T7, the T7pol transcribes the nucleic acids-to-be-expressed from the plasmid vector. The vaccinia MVA amplifies the plasmid-nucleic acid construct resulting in an increased intracellular template concentration for T7pol

5 transcomplementation and increased antisense RNA, ribozyme, polypeptide or fusion polypeptide expression.

Other systems for the expression of nucleic acids functionally linked to T7 RNA polymerase or other bacteriophage promoters (SP6 or T3) may also be used. Nucleic acid expression can be performed with a recombinant retrovirus vector containing the nucleic acid-to-be-expressed functionally linked to a T7 RNA polymerase promoter (T7pro) and T7 terminator. This expression cassette is flanked by 5' and 3' LTRs, a packaging signal and includes the T7pol gene, that encodes a T7pol that contains a nuclear localization signal (T7pol-nls), functionally linked to a eukaryotic promoter. In this system, the expressed T7 protein is transported to the nucleus for nucleic acid transcription. Because of the high transcriptional activity of T7pol, high intracellular levels of polypeptide, fusion polypeptide, antisense RNA or ribozyme can be achieved. In another embodiment, antisense RNA or ribozyme can be fused to another ribozyme that acts intramolecularly to free the antisense RNA or ribozyme targeting the nucleic acid of interest.

Transfection of nucleic acid (DNA or RNA) into cells is required for either packaging of recombinant vectors into virus particles or direct transfection of plasmids that express antisense RNA, ribozymes, polypeptides or fusion-polypeptides into target host cells can be mediated by a variety of chemicals including calcium-phosphate, polybrene, DEAE-dextran, and liposomes. The calcium-phosphate method includes contacting the surface of the cell with a calcium phosphate-DNA co-precipitate. Polycations such as polybrene or DOSPER (Boehringer-Mannheim) also can be used to increase the efficiency of transfection of low molecular weight DNA. Liposomes are available from a variety of commercial suppliers and include DOTAP™ (Boehringer-Mannheim), Tfx™-50, Transfectam®, ProFection™ (Promega, Madison WI), and LipofectAmin™, Lipofectin®, LipofectAce™ (GibcoBRL, Gaithersburg, MD). In solution, the lipids form vesicles that associate with the nucleic acid and facilitate its transfer into cells by fusion of the vesicles with cell membranes or by endocytosis. Alternatively, DNA can be introduced into cells by electroporation. Each of these systems differ in their transfection efficiency for a given cell line. If transfection

conditions for a given cell line have not been established or are unknown, they can be determined empirically (Maniatis *supra*).

The target host cell can be any cell of interest that expresses a disease associated phenotype or a phenotype that can be differentiated from a "normal" or control cell. For example, the host cell can be a mammalian cell, a plant cell or a microorganism. If a tumor cell expresses genes, for example, *H-ras*, that are not expressed in normal cells, antisense RNA or ribozymes targeting these genes are constructed and expressed in the tumor cells that are then assayed for an altered cell phenotype. The altered phenotype may be reduced cell growth, reduced DNA synthesis, increased synthesis of a protein(s), chemical responsiveness, morphologic changes. Tumor cells have been shown to differentially express between 138-500 genes compared to their non-tumorigenic counterparts. Examples of tumor cells are EJ (bladder carcinoma), FEM (melanoma), RT-4 (bladder carcinoma), MCF-7 (breast carcinoma), PC3 (prostate carcinoma). Examples of genes expressed in tumor cells are *fos*, *H-ras* or the estrogen receptor. Proteins that regulate gene expression in tumor cells also can be identified. For example, this can be accomplished by monitoring the expression of a reporter gene expressed from a promoter that is active in tumor cells in the presence of antisense RNA or ribozymes targeted to a gene of interest. Conversely, for gene(s) that are expressed in particular normal cells but are not expressed in tumor cells, antisense RNA or ribozymes can be expressed in the normal cells which are then assayed for an altered phenotype. In either approach, gene(s) associated with disease pathways or phenotypes can be identified.

For determining the function of the gene of interest, the tumor or target cells are evaluated for an alteration in their phenotype. Examples of phenotypic changes that can be evaluated include cell viability, replication, morphologic changes, membrane permeability, protein expression or the expression of biologically active compounds (e.g., steroids), proliferation, drug susceptibility, expression of cell surface molecules such as receptor molecules and antigens. In order to evaluate an alteration in cell phenotype, any of a variety of methods can be used, depending at least in part on the amount of information available concerning the putative function of a product encoded by a target nucleic acid.

In host cells amplifying and expressing polypeptides, fusion-polypeptides, antisense RNA or ribozymes, phenotypic change can be monitored directly. For example, if a product of the target nucleic acid prevents apoptosis is inhibited by a ribozyme or antisense RNA, the host cell will undergo specific types of morphologic changes, such as nuclear condensation,

following oligonucleotide DNA expression. The function of cellular or viral genes also can be identified that are involved in virus replication. Antisense RNA and ribozyme families can be designed to viral genes or cellular genes whose expression is altered by virus infection. If the product of the targeted nucleic acid affects replication, virus titers may increase or  
5 decrease. If the product of the nucleic acid is involved in drug susceptibility, this function can be identified by monitoring cells for altered resistance or susceptibility to various drugs.

Amplification and expression of a fusion polypeptide or polypeptide encoded in a host cell by a target nucleic acid can enhance or inhibit cellular functions associated with a phenotype of interest. In either instance, an altered phenotype is produced that can be used to  
10 assign a function to the sample nucleic acid sequence.

The observed changes a cell undergoes as a result of oligonucleotide DNA expression can be monitored by various methods. Stains can be employed if the decreased expression of a targeted gene affects cell viability or membrane permeability. The expression of a reporter gene operatively linked to a promoter that is regulated by the product of the targeted nucleic  
15 acid can also be used. If the product of the target nucleic acid affects cell cycle regulation and transformation this can be monitored by measuring the incorporation of a labeled nucleotide into the cell. Antibody-based assays can be employed to detect the presence or absence of a protein of interest coded for by a nucleic acid of interest. Additional types of assays can be employed depending on the phenotype or cellular property that is being analyzed.

20 Phenotypic change can be monitored indirectly, for example, by evaluating ribozyme activity by comparing the targeted mRNA levels in cells expressing and cells that do not express one or more members of the ribozyme family designed to inhibit the function of the targeted mRNA and its encoded product. Total cellular or cytoplasmic RNA can be purified by a variety of methods (Maniatis *supra* pp. 7.6-7.29) and analyzed by Northern or dot blot  
25 (Maniatis *supra* pp. 7.37-7.57). mRNA can be assayed by reverse transcription-PCR employing primers that hybridize with the targeted mRNA. The absence or decreased production of a PCR product is indirectly indicative of ribozyme activity (Baier *et al.* 1994, *Molecular Immunology* 31:923-932). Similar methods can be used to evaluate antisense RNA expression. Because antisense RNA does not act catalytically to cleave its target  
30 mRNA, antisense expression can be monitored by treating the purified RNA with an nuclease specific for double-stranded RNA followed by Northern blot, dot blot or reverse transcription-PCR. To monitor the expression of a polypeptide or fusion polypeptide, protein

electrophoresis, antibody-based assays, Northern blots, and reverse-transcription PCR can be utilized to detect either the polypeptide or fusion polypeptide directly or the encoding mRNA.

The methods and compositions of the subject invention can be used to identify the function of genes. The function of genes can be identified that are involved in virus replication or life cycle. If the product of the targeted nucleic acid affects replication, virus titers may increase or decrease. In this example the target gene can be a cellular or a viral gene. If the targeted nucleic acid is in a bacteria or microorganisms, determining their function identifies new pathways and lead to the identification of targets for new antimicrobials.

The following examples are offered by way of illustration and not by way of limitation.

## EXAMPLES

### Example 1

#### Ribozyme Design

The purpose of this experiment was to design a oligonucleotide family encoding ribozymes that would cleave the EGFP mRNA (Clontech, Palo Alto, CA) (SEQ.ID NO. 1). Twenty ribozymes were prepared to target at approximately equidistant points in the GFP mRNA sequence from a putative GUN (N=A, G, C, U) optimum cleavage site (Kashani-Sabet and Scanlon, (1995) *Cancer Gene Therapy* 2:213 -223).

An oligonucleotide family for ribozyme expression, Figure 1A-1C, were made in a 96-well matrix using parallel array technology and annealed to form double-stranded DNA with unique *Hind* III and *Cla* I sites at each of the 5' and 3' ends, respectively, for ligation into a retrovirus vector. An example of two complementary oligos is as follows, with the catalytic core from a hammerhead ribozyme in bold. The underlined region is the ribozyme binding sequence when expressed as RNA that is complementary to a mRNA sequence of EGFP. (SEQ ID NOS:21-22)

```

5'  AGCTT CCAGCTC  CTGATGAGTCCGTGAGGACGAA ACCAGGA  AT    3'
30  3'      A GGTCTGAG  GACTACTCAGGCACTCCTGCTT TGGTCCT  TAGC  5'

```

To anneal the complementary oligonucleotides, approximately 1.0 microgram of each set shown in Table 1 were dissolved in water and mixed at a one to one molar ratio in a 96-well microtiter plate at room temperature. The 5' end (left end) of the double-stranded DNA

fragment overlaps with an *Hind* III restriction enzyme site. The 3' end of the fragment (right end) overlaps with a *Cla* I site.

### Example 2

#### 5                    Preparation of a Family of Retrovirus Plasmid Vectors

The purpose of this experiment was to prepare a family of retrovirus plasmid vectors comprising a double-stranded DNA encoding a ribozyme to EGFP mRNA. pLNCX, (50 micrograms, Clontech, Palo Alto, CA), which contains an extended viral packaging signal, multiple cloning site and neomycin resistance gene flanked by the Moloney murine leukemia virus 5' and 3' long terminal repeats and an ampicillin resistance gene was digested with restriction enzymes, *Hind* III and *Cla* I. Approximately, 0.5 to 2 µg of digested plasmid was placed into a well of a multi-well (e.g. 96 well) plate. The family of annealed oligonucleotides, were added individually at 4 to 6 fold excess of the *Hind* III/*Cla* I treated pLNCX. The oligonucleotide DNA was ligated into pLNCX by adding a tenth volume of 10X T4 DNA ligation buffer and T4 DNA ligase. The final concentration of the ligation buffer components and T4 DNA ligase were: 0.05 M Tris-HCl (pH 7.6), 10 mM MgCl<sub>2</sub>, 10 mM dithiothreitol (DTT), 50 µg/ml bovine serum albumin (Fraction V; optional), 1.0 mM ATP, 0.05 Weiss units of bacteriophage T4 DNA ligase per microliter. The ligation was performed for 4-8 hours at 16°C.

### Example 3

#### 20                    Transfection of Mammalian Cells Using Retrovirus Plasmid Vector

The purpose of this experiment was to package the family of retrovirus virus plasmid constructs from Example 2 into retrovirus virus particles. Using the Calcium phosphate precipitation method (Keck, *et al.* (1990) *Cell* 61:801-809, Cochran, *et al.* (1985) *Proc. Natl. Acad. Sci. (USA)* 82:19-23) for transfecting DNA into mammalian cells, 0.1 to 0.5 micrograms of ligated plasmid/oligo DNAs from Example 2 was transfected per well of a 96-well plate containing 100 µl of minimal essential media (MEM) supplemented with 10% fetal calf serum (FCS) and approximately 1,000 to 25,000 PT67 cells. Four hours later the media was replaced with fresh MEM supplemented with 10% FCS and incubated at 37°C for 48 hours. The retrovirus vector contains a neomycin resistance gene; therefore, G418 selection can be used to obtain a population of cells that stably express the transfected vector and to monitor virus titers. Recombinant retrovirus production can be monitored by titering aliquots

of the transfected cell supernatant in a focus forming assay whereby cells infected with the recombinant retrovirus become resistant to G418 (Clontech, Palo Alto, CA). When virus titers  $>10^5$ /ml were reached, usually between 2-7 days, the viruses are infected into target cells, CHO-AA8- Tet-Off cells (Clontech, Palo Alto, CA), expressing EGFP (CHO-EGFP).

5

#### Example 4

##### Analysis of Ribozyme Activity

This experiment was designed to demonstrate the inactivation of EGFP expression in target host cells infected with a family of recombinant retrovirus vectors that express  
10 ribozymes targeted to various regions of the EGFP mRNA. Ribozyme activity is inversely proportional to EGFP expression. The ribozyme hybridizes to and cleaves the EGFP mRNA, thereby, reducing protein expression. EGFP was assayed fluorescence by an automated Fluorescence Activated Cell Sorter.

CHO-EGFP cells (Clontech, Palo Alto, CA) were cultured to near confluency in 96-  
15 well plates in MEM with 10% FCS. The family of recombinant retroviruses from Example 3 were used to individually infect (one recombinant retrovirus/well) CHO-EGFP cells. The multiplicity of infection (virus particle per cell ratio) was about 5-10 to insure that every cell was infected with at least one virus particle. Infection of target cells was enhanced with polybrene (10 micrograms/ml), a polycation that acts by neutralizing the net negative surface  
20 charges on the virus and cells (Stoker, "Retroviral Vectors" In Molecular Virology: A Practical Approach, Davison and Elliott, eds., p 187). Mock infected cells served as controls. Following infection, the cells were incubated for 48 hours at 37°C and then assayed for EGFP expression.

EGFP expression was assayed by using an incident light at 488 nm and measuring the  
25 emitted light at 507 nm. The emitted or observed light is detected in using the appropriate set of filters, corresponding to the incident and emitted light and a Wallac-Victor Machine or by a Fluorescence Activated Cell Sorter (FACS).

#### Example 5

##### Preparation of Plasmid Vector for Non-Retroviral Transfection

This example discloses the construction of plasmid vectors that express the family of ribozymes without the need for a bacterial cloning step. The family of EGFP ribozymes were ligated into the multiple cloning site of pCEP4 (Invitrogen, San Diego, CA) operatively  
30

linked to the CMV promoter and SV40 polyadenylation signal. pCEP4 is an Epstein Barr virus (EBV)-based vector that is maintained extrachromosomally in primate and canine cell lines. pCEP4 contains nuclear antigen, EBNA-1, for high-copy episomal replication of the plasmid by the EBV origin of replication, *oriP*, and the hygromycin resistance gene for stable maintenance of the vector. In this example, the oligonucleotides are designed to contain *Hind* III and *Bam*HI sites to facilitate ligation into the expression vector. The synthesis, annealing and ligation procedures are the same as those described for the retrovirus vectors in Example 1.

### Example 6

#### Transfection of Mammalian Cells (Non-Retroviral-Mediated Transfection)

This experiment demonstrates the delivery of plasmid DNA encoding the EGFP ribozyme family directly to mammalian cells, thereby, eliminating the use of *E. coli* to amplify the plasmid and increasing the throughput of ribozyme sequences that can be examined. pCEP4 DNAs containing the EGFP ribozyme family were introduced into host cells by calcium-phosphate precipitation (Cochran *et al.* (1985) *Proc. Natl. Acad. Sci. (USA)* 82:19-23, Keck *et al.* (1990) *Cell* 61:801-809). The pCEP4 DNA can be treated with gyrase (Mizuuchi *et al.* (1984) *J. Biol. Chem.* 259:9199-9201; Bates *et al.* (1996) *Biochemistry* 35:1408-1416) to increase the transfection efficiency. In either case, by increasing the amount of transfected DNA from the ligation reaction, more than one ribozyme targeted to a specific sequence can be transfected per cell. This insures that the gene of interest is inactivated and produces an altered phenotype.

### Example 7

#### Analysis of Ribozyme Activity

This experiment was designed to demonstrate the inactivation of EGFP expression in target cells infected with a family of recombinant plasmid vectors that express a family of ribozymes targeted to various regions of the EGFP mRNA. Ribozyme activity is inversely proportional to EGFP expression. The ribozyme hybridizes to and cleaves the EGFP mRNA, thereby, reducing protein expression. EGFP was assayed according to the procedure described in Example 4.

CHO-EGFP cells (Clontech, Palo Alto, CA) were cultured to near confluency 96-well plates in Minimal Essential Media (MEM) supplemented with 5% fetal calf serum (FCS).

The family of recombinant plasmids from Example 6 were used to individually and in pools to transfect CHO-EGFP cells. Approximately, 0.1-0.5 micrograms of plasmid DNA was transfected per well to insure that every cell was transfected with at least one plasmid. Mock transfected cell served as controls. Following transfection, the CHO-EGFP cells were

5 incubated for 48-72 hours. EGFP was assayed in Example 4.

### Example 8

#### Ribozyme Vector Design with Double-Stranded Oligonucleotides

This experiment was designed to demonstrate the feasibility of novel ribozyme vector production by incorporation of a double-stranded oligonucleotide encoding a ribozyme into a

10 delivery vector followed by site-directed mutagenesis.

Plasmids pGEM-5Zf (-) (Promega) and pGEMEX-1 (Promega) were digested with restriction enzymes *NotI/NsiI* and *NotI/ApaI*, respectively, and treated with calf-intestine alkaline phosphatase to dephosphorylate the plasmids. Oligo1 (5' GGCCGAATTCCT

15 GATGAGGCAGTGATGCCGAAAAGCTTTGCA 3'), SEQ ID NO:23, oligo2 (5' pGGCCGAATT CCTGATGAGGCAGTGATGCCGAAAAGCTTGGCC 3'), SEQ ID NO:24, and oligo3 (5' pAAGCTTT TCGGCATCACTGCCTCATCAGGAATTC 3'), SEQ ID NO:25, were synthesized with a 5' phosphate and obtained from Operon Technologies, Inc. Oligo1 and oligo3 were annealed at a 1:1 molar ratio at room temperature to form a

20 double-stranded DNA molecule with unique *NotI* and *NsiI* sites at the ends as demonstrated below,

Oligo1: 5' GGCCGAATTCCTGATGAGGCAGTGATGCCGAAAAGCTTTGCA 3'  
 Oligo3: 3' CTTAAGGACTACTCGTCACTACGGCTTTTCGAA 5'

25

while oligo2 and oligo3 were annealed for fifteen minutes at a 1:1 molar ratio at room temperature to form the following double-stranded DNA molecule with unique *NotI* and *ApaI* sites at the ends.

30 Oligo2: 5' GGCCGAATTCCTGATGAGGCAGTGATGCCGAAAAGCTTGGCC 3'  
 Oligo3: 3' CTTAAGGACTACTCGTCACTACGGCTTTTCGAA 5'

Oligo1/3 and oligo2/3 were ligated for one hour at room temperature into *NotI/NsiI* cleaved pGEM and *NotI/ApaI* cleaved pGEMEX at a 4:1 molar ratio respectively, with the Epicentre



Fast-Link DNA Ligation Kit following the manufacturer's protocol. HB101 competent cells (Life Technologies) were transformed with the ligation reactions by heat shocking at 42°C, plated on LB/Amp plates and incubated at 37°C. Isolated colonies were picked and inoculated into 3 ml. of LB/Amp media and incubated at 37°C overnight. Miniprep plasmid DNA was extracted from the overnight cultures with QIAGEN's QIAprep Spin Miniprep Kit according to the manufacturer's protocol.

Plasmids that contained the proper insert were identified on the basis of a diagnostic restriction enzyme analysis. pGEM-oligo1/3 was cleaved with *HindIII* which linearized the vector, while pGEMEX-oligo2/3 was cleaved with *PvuII* which cleaved the vector resulting in the formation of three DNA fragments which were visualized after agarose gel electrophoresis. Plasmids that contained the proper insert were selected for site-directed mutagenesis following Stratagene's QuikChange Site-Directed Mutagenesis Kit. pGEM-oligo1/3 was combined with primers pGEM.Sca (5' TACTCAAGCTATGCAAGTACTT TCGGCATCACTGCCTCATC 3'), SEQ ID NO:26, and pGEM.Pvu (5' ATCACTA GTGCGGCCAGCTGCTGATGAGGCAGTGATGCCG 3'), SEQ ID NO:27, while pGEMEX-oligo2/3 was combined with primers pGEMEX.Sma (5' CGAGGGATCCG GGCCCCGGGTTCGGCATCACTGCCTCATC 3'), SEQ ID NO:28, and pGEMEX.Kpn (5' CTTATGCATGCGGCCGGTACCCTGATGAGGCAGTGTGATGCCG 3'), SEQ ID NO:29. The primers were complementary to the plasmid templates except for sequences encoding unique restriction sites that were engineered into the primers and propagated in the polymerase chain reaction (PCR) products. The PCR was performed under the following cycling parameters: 1 cycle at 95°C. for 30 sec.; 18 cycles at 95°C. for 30 sec., 55°C. for 60 sec., 68°C. for 6 min.; and a hold cycle at 4°C. The non-mutated template DNA was then eliminated by digestion with *DpnI* enzyme. DH5α Max Efficiency competent cells (Life Technologies) were transformed with the mutated PCR products, plated on LB/Amp agar plates and incubated at 37°C. overnight. Isolated colonies were selected; miniprep cultures were grown in LB/Amp at 37°C overnight. Miniprep DNA was extracted from the overnight cultures with QIAGEN's QIAprep Spin Miniprep Kit according to the manufacturer's protocol. pGEM-Sca/Pvu plasmid DNA was cleaved with either *PvuII* alone or *ScaI* alone to identify plasmids that contained the proper insert. pGEMEX-Sma/Kpn plasmid DNA was cleaved with *SmaI* and visualized after agarose gel electrophoresis to identify those plasmids that contained an insert. Plasmids with inserts were sequenced to confirm the presence of the mutation. As shown in Fig. 2, pGEM-Sca/Pvu contained the mutated sequence. pGEMEX-

Sma/Kpn contained the correctly mutated insert, while the parental plasmid (pGEMEX-oligo2/3), which was not subjected to mutagenesis, contained the wild type sequence.

### Example 9

#### 5                    Ribozyme Vector Design With Single-Stranded Oligonucleotides

This experiment was designed to demonstrate the feasibility of producing novel ribozyme-vectors by ligating into linearized expression vectors single-stranded oligonucleotides encoding novel ribozymes.

Oligo1 was ligated into *NotI/NsiI* cleaved pGEM and oligo2 was ligated into the  
10 *NotI/ApaI* cleaved pGEMEX plasmid at a 4:1 molar ratio for one hour at room temperature with the Epicentre Fast-Link DNA Ligation Kit following the manufacturer's protocol. DNA was purified by phenol:chloroform extraction and ethanol precipitation. The vacuum-dried DNA pellet was resuspended with QH<sub>2</sub>O. Half of the purified DNA was treated with Klenow so as to fill in the missing complementary strand of the incorporated oligonucleotide; the  
15 other half was not treated with Klenow. The sample treated with Klenow was further purified by phenol:chloroform extraction.

PCR was used to determine if oligo1 and oligo2 were ligated correctly into the vectors. Three microliters of either the Klenow-treated (filled in) template or non-Klenow-treated (not filled in) template were subjected to PCR. pGEM-oligo1 was amplified with  
20 either pGEM.for.1 (5' TTGGGCCCCGACGTCGCATG 3'), SEQ ID NO:30, or pGEM.for.2 (5' GAATTGGGCCCCGACGTCGC 3'), SEQ ID NO:31, combined with pGEM.rev (5' TGTGAGCGGATAACAATTTCACAC 3'), SEQ ID NO:32. pGEMEX-oligo2 was amplified with pGEMEX.for primer (5' GAATACTCAAGCTTATGCATG 3'), SEQ ID NO:33, and pGEMEX.rev primer (5' GAGGTTGTAGAAGTTCCGC 3'), SEQ ID NO:34.  
25 The PCR reaction mixtures contained 50 pmoles of each of the forward and reverse primers, 10 mM dNTPs, and 1U of Taq polymerase in a 50 uL. reaction mixture under the following cycling parameters: 1 cycle at 95°C. for 5 min.; 30 cycles at 95°C. for 30 sec., 55°C. for 30 sec., 68°C. for 1 min.; and a hold cycle at 4°C. Visualization of the PCR products derived from both templates after agarose gel electrophoresis confirmed that oligo1 and oligo2 were  
30 properly ligated into the vectors.

Max Efficiency DH5α competent cells (Life Technologies) were transformed with 1 uL. from both samples (filled-in and not filled-in) from each vector by heat shocking at 42°C, plated on LB/Amp plates, and incubated overnight at 37 C. Positive colonies were inoculated

into 3 ml. LB/Amp cultures and incubated at 37°C overnight. Plasmid miniprep DNA was isolated with QIAGEN's QIA prep Spin Miniprep Kit and subjected to sequence analysis. As shown in Fig. 3, each plasmid (Klenow treated or not Klenow treated) obtained from the pGEMEX vector contained the properly ligated oligonucleotide in the now double-stranded, circularized ribozyme vector. pGEMEX-oligo2 clones contained the appropriate insert while clones from the parental pGEMEX plasmid did not.

### Example 10

#### Ribozyme Vector Design With Triple-Stranded Oligonucleotides

This experiment was designed to demonstrate a novel method for production of ribozyme vectors by ligation of triple-stranded oligonucleotides encoding novel ribozymes into expression vectors.

pGEM was digested with restriction enzymes *NotI/ApaI* while pGEMEX was digested with *NotI/NsiI*. The linearized plasmids were treated with calf-intestine alkaline phosphatase to dephosphorylate the plasmids. Oligo4 (5' CATCAGGAATTCGGCCGGCC 3'), SEQ ID NO:35, oligo5 (5' GGCCTGCAAAGCTTTTCGG 3'), SEQ ID NO:36, and oligo6 (5' CATCAGGAATTCGGCCTGCA 3'), SEQ ID NO:37, were treated with T4 polynucleotide kinase to phosphorylate the 5' end of each oligonucleotide and facilitate ligation. Oligo1, oligo4 and oligo5 were annealed for approximately fifteen minutes at a 1:1:1 molar ratio to form the following triple-stranded oligonucleotide.

5' → 3'

Oligo1: GGCCGAATTCCTGATGAGGCAGTGATGCCGAAAAGCTTTGCA

Oligo4: CCGGCCGGCTTAAGGACTAC GGCTTTTCGAAACGTCCGG : Oligo5

3' ← 5'

3' ← 5'

Oligo1, oligo5 and oligo6 were annealed at a 1:1:1 molar ration at room temperature for approximately 15 minutes to form the following triple stranded oligonucleotide.

5' → 3'

Oligo1: GGCCGAATTCCTGATGAGGCAGTGATGCCGAAAAGCTTTGCA

Oligo6: ACGTCCGGCTTAAGGACTAC GGCTTTTCGAAACGTCCGG : Oligo5

3' ← 5'

3' ← 5'

Oligo1/4/5 and oligo 1/5/6 were ligated into *NotI/ApaI* cleaved pGEM vector and *NotI/NsiI* cleaved pGEMEX vector, respectively, at either a 5:1 or 6:1 molar ratio using T4 DNA ligase

at 400 u/microliter (New England Biolab). After an overnight incubation at 16°C., the ligation reaction was divided into two equal parts. One part was treated with Klenow to fill in the nicks between the oligonucleotides. The other half of the ligation reaction was not treated with Klenow. The Klenow-treated DNA was purified by phenol:chloroform extraction.

5 PCR was used to determine if the oligonucleotides were correctly ligated into the vector. Three microliters of either the Klenow-treated template or non-Klenow-treated template were subjected to PCR with pGEM.for.2 and pGEM.rev primers (pGEM-oligo1/4/5 template) or pGEMEX.for and pGEMEX.rev primers (pGEMEX-oligo1/5/6 template) in a PCR reaction mixture containing 50 pmoles of each forward and reverse primer, 10 mM  
10 dNTPs, and 1U of Taq polymerase in a 50 uL. volume under the following parameters: 1 cycle at 95°C. for 5 min.; 30 cycle at 95°C. for 30 sec., 55°C. for 30 sec., 68°C. for 1 min.; and a hold cycle at 4°C. Visualization of the PCR products (5 uL.) derived from pGEMEX-oligo1/5/6, after agarose gel electrophoresis, confirmed that the three oligonucleotides were properly ligated into the vector. The PCR products from the filled-in ligation reactions were  
15 not notably different from the non-filled-in ligation reactions. PCR products from pGEM-oligo1/4/5 were not amplified.

Max Efficiency DH5 $\alpha$  competent cells (Life Technologies) were transformed with both samples (filled-in and not filled-in) from the pGEMEX-oligo1/5/6 vector by heat shocking at 42°C, plated on LB/Amp plates and incubated overnight at 37°C. Positive  
20 colonies (from each sample) were inoculated into 3 ml. of LB/Amp. Plasmid miniprep DNA was isolated from each culture with QIAGEN's QIAprep Spin Miniprep Kit and subjected to sequence analysis. As shown in Fig. 4, each plasmid (Klenow treated or not Klenow treated) from pGEMEX-oligo1/5/6 contained the properly ligated oligonucleotides in the new ribozyme vector.

25

### Example 11

#### Construction of Marker Plasmid

This experiment was designed to disclose the construction of plasmids encoding a gene of interest (EGFP) that can be cloned directly in non-bacterial cells. Sequences encoding green fluorescent protein were ligated into an expression vector. Mammalian cells  
30 were transfected with the purified vector and fluorescence was measured as an indication of the level of expression of green fluorescent protein.

The plasmid pLEIN(Clontech) is a Moloney Murine Leukemia Virus derived retroviral vector containing a sequence encoding green fluorescent protein (EGFP) under the

control of the 5' viral LTR promoter. 100 µg of pLEIN was digested with 100 units of *EcoRI* restriction enzyme for 3.5 hours at 37°C. The digested DNA was run on a 1% agarose gel to confirm that the digestion reaction had gone to completion. Distinct bands for the vector and the insert (EGFP) were identified. The DNA was purified by phenol chloroform extraction.

- 5 The purified DNA was incubated with ligase in the presence of ATP at 16°C overnight. Visualization of the ligation reaction mixture on a 1% agarose gel confirmed that the vector and insert had been religated.

### Example 12

#### 10 Non-Bacterial Cloning of Marker Plasmid

This experiment was designed to demonstrate that non-bacterial cloning of plasmid DNA containing a gene of interest (EGFP) was sufficient for expression of the gene. Nxa cells were plated at  $8 \times 10^4$  cells per well in a 24 well plate one day prior to the transfection.

- 15 Two hours prior to the transfection, the medium was aspirated from each well and replaced with 1.6 mL of fresh medium. Using the calcium phosphate co-precipitation method, one microgram or five micrograms of supercoiled DNA, cut DNA (not ligated), or religated DNA was transfected into cells of the respective wells. Fresh medium was added to each well three hours after transfection. Cells were incubated at 37°C and 5% CO<sub>2</sub> for 48 hours at which
- 20 point the cells were observed for expression of green fluorescent protein under a fluorescence microscope. Cells that were transfected with cleaved unligated DNA showed only a low background level of EGFP expression (green fluorescence). Cells that were transfected with one microgram of religated plasmid DNA showed good expression of GFP while cells that were transfected with five micrograms of religated plasmid demonstrated an even brighter
- 25 green fluorescence. As a positive control, cells that were transfected with either one or five micrograms of supercoiled, uncut DNA showed very bright green fluorescence. These results demonstrated that direct cloning of plasmid DNA in non-bacterial cells was sufficient for expression of green fluorescent protein.

30

The subject invention discloses methods and compositions for the high-throughput delivery and intracellular expression of nucleic acids to determine the function of a product(s) encoded by a target nucleic acid of interest. Methods are described for the construction of vectors that express nucleic acids that encode either polypeptides, fusion polypeptides,

antisense RNAs or ribozymes; the ligation of the nucleic acids-to-be-expressed into either retrovirus vectors or plasmid vectors; the packaging of the recombinant vector into retrovirus particles; the expression of the encoded family from cells either infected with the retrovirus particles or cells directly transfected without a bacterial amplification step with the  
5 recombinant plasmid expression vectors. The results demonstrate that a family of oligonucleotide DNA expressing a ribozyme from either recombinant retrovirus or recombinant plasmid expression vectors inactivate a gene of interest to produce an altered cellular phenotype.

All publications and patent applications mentioned in this specification are indicative  
10 of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now having been fully described, it will be apparent to one of ordinary  
15 skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended Claims.

WHAT IS CLAIMED IS:

1. A method for high-throughput amplification of one or more members of an oligonucleotide family which is related to a sample nucleic acid, said method comprising:  
growing a multiplicity of recombinant non-bacterial cell cultures containing an  
5 expression vector comprising at least one member of said oligonucleotide family whereby  
said member is transcribed and the number of copies of said oligonucleotide is amplified in  
each of said non-bacterial cell cultures.
2. The method according to Claim 1, wherein a transcription product of said one or  
10 more members of said oligonucleotide family is a ribozyme designed to cleave a target  
nucleic acid expressed by said non-bacterial cell cultures, wherein said target nucleic acid  
comprises a nucleotide sequence of said sample nucleic acid.
3. The method according to Claim 1, wherein a transcription product of said one or  
15 more members of said oligonucleotide family is an antisense nucleic acid designed to bind to  
a target nucleic acid expressed by said non-bacterial cell cultures, wherein said target nucleic  
acid comprises a nucleotide sequence of said sample nucleic acid.
4. The method according to Claim 1, wherein said recombinant non-bacterial cell  
20 cultures comprise mammalian cells.
5. The method according to Claim 1, wherein said expression vector is a plasmid or a  
virus.
6. The method according to Claim 5, wherein said virus is a retrovirus, or an adeno-  
25 associated virus.
7. The method according to Claim 1, wherein said sample nucleic acid is a genomic  
DNA, a cDNA, an essential sequence tag (EST), or an RNA.
- 30 8. A method of assigning a function to a product coded for by a sample nucleotide  
sequence, said method comprising:  
growing a cell culture comprising one or more host cell(s) wherein said host cells  
express a target nucleic acid comprising said sample nucleotide sequence and wherein said

host cells contain one or more members of a family of nucleic acids which bind to a transcription product of said nucleotide sequences whereby transcription product of said target nucleic acid is inhibited and said host cell exhibits at least one phenotypic change analyzing phenotypic changes in said cell to identify one or more altered function(s);

5 and

obtaining a nucleotide sequence of said target nucleic acid, whereby a function is assigned to said sample nucleotide sequences.

9. The method according to Claim 8, wherein said function is a physiological  
10 function.

10. The method according to Claim 8, wherein said function is enzyme activity.

11. The method according to Claim 8, wherein said function is protein synthesis.  
15

12. The method according to Claim 8, wherein said function is expression of a biological factor.

13. The method according to Claim 8, wherein said function is a regulatory effector  
20 function.

14. The method according to Claim 8, wherein said function is altered directly.

15. A double-stranded DNA comprising:  
25 a sense strand and an antisense strand, wherein said sense strand codes for an antisense strand which when expressed as RNA binds to a mRNA sequence transcribed from a target nucleic acid sequence so that expression of a product of said target nucleic acid is inhibited, wherein a means for determining directionality of expression is included in said double-stranded DNA.

30

16. The double-stranded DNA according to Claim 15, wherein said RNA comprises a catalytic domain which when expressed as RNA cleaves a mRNA sequence transcribed from



a target nucleic acid, and binding sequences flanking said catalytic domain for binding said RNA to said mRNA.

17. The double-stranded DNA according to Claim 16, wherein said RNA is a  
5 ribozyme.

18. The double-stranded DNA according to Claim 15, wherein said means for  
determining directionality of expression comprises a different non blunt-ended restriction  
enzyme site at each end of said double-stranded DNA.

10

19. The double-stranded DNA according to Claim 18, wherein said double-stranded  
DNA is formed by contacting a first oligonucleotide with a complementary second  
oligonucleotide.

20. The double-stranded DNA according to Claim 19, wherein said non blunt-ended  
restriction enzyme site is complementary to an end of said expression vector.

21. A delivery vector comprising the double-stranded DNA according to Claim 15,  
wherein said delivery vector is formed by contacting a double-stranded oligonucleotide with  
20 an expression vector.

22. A delivery vector comprising the double-stranded DNA according to Claim 15,  
wherein said delivery vector is formed by contacting a single-stranded oligonucleotide with  
an expression vector.

25

23. A delivery vector comprising the double-stranded DNA according to Claim 15,  
wherein said double-stranded DNA is formed by contacting a triple-stranded oligonucleotide  
with an expression vector.

24. The triple-stranded oligonucleotide according to Claim 23, wherein said triple-  
stranded oligonucleotide is formed by contacting a first oligonucleotide, a second  
oligonucleotide and a third oligonucleotide, wherein said second oligonucleotide is  
complementary to nucleotides at the 5' end of said first oligonucleotide, wherein said second

30

oligonucleotide further comprises excess nucleotides extending beyond the 5' end of said first oligonucleotide, wherein said third oligonucleotide is complementary to nucleotides at the 3' end of said first oligonucleotide, and wherein said third oligonucleotide contains excess nucleotides that extend beyond the 3' end of said first oligonucleotide.

5

25. The triple-stranded oligonucleotide according to Claim 24, wherein said excess nucleotides are complementary to and base pair with the ends of said expression vector.

26. The double-stranded DNA according to Claim 22 or Claim 23, wherein said  
10 expression vector is filled in with Klenow.

27. The double-stranded DNA molecule according to Claim 21, Claim 22, or Claim 23, wherein said expression vector further comprises regulatory elements for expression.

15

28. A retrovirus expression vector comprising:  
a retrovirus plasmid vector comprising a double-stranded DNA according to Claim 15.

20

29. The retrovirus expression vector according to Claim 28, wherein said vector comprises supercoiled DNA.

30. A retrovirus packaging cell line comprising:  
a retrovirus expression vector according to Claim 28.

25

31. A retrovirus particle comprising:  
a genome encoding expression of an RNA comprising a catalytic domain for cleavage of a mRNA transcribed from a target nucleic acid, and binding sequences flanking said catalytic domain for binding said RNA to said mRNA.

30

32. A mammalian cell comprising:  
one or more double-stranded DNA(s) comprising a sense strand and an antisense strand, wherein said sense strand codes for a catalytic domain which when expressed as RNA cleaves a mRNA sequence transcribed from a target nucleic acid, and binding sequences

flanking said catalytic domain for binding said RNA to said mRNA, and wherein a means for determining directionality of expression is included in said one or more double-stranded DNA(s).

5           33. An adeno-associated virus expression vector comprising:  
            an adeno-associated virus plasmid vector comprising a double-stranded DNA  
            according to Claim 15.

            34. An adeno-associated virus packaging cell line comprising:  
10           an adeno-associated virus plasmid vector according to Claim 33 and an adeno-  
            associated virus helper plasmid.

            35. An adeno-associated virus comprising:  
            a genome encoding the expression of an RNA comprising a catalytic domain for  
15           cleavage of a mRNA transcribed from a target nucleic acid, and binding sequences flanking  
            said catalytic domain for binding said RNA to said mRNA.

            36. A plasmid expression vector comprising:  
            a double-stranded DNA according to Claim 15.

20           37. A method for the introduction into a host cell(s) of a plasmid expression vector,  
            said method comprising:  
            contacting a cell culture comprising one or more host cell(s) with a co-precipitate of  
            calcium phosphate and a double-stranded DNA comprising a sense strand and an antisense  
25           strand, wherein said sense strand codes for a catalytic domain, which when expressed as RNA  
            cleaves a mRNA sequence transcribed from a target nucleic acid, and binding sequences  
            flanking said catalytic domain for binding said RNA to said mRNA, and wherein a means for  
            determining directionality of expression is included in said double-stranded DNA, whereby  
            said plasmid expression vector is introduced into said host cells.

30           38. The method according to Claim 37, wherein said host cell(s) comprise  
            mammalian cell(s).

39. The method according to Claim 37, wherein said plasmid expression vector is supercoiled DNA.

40. A method for expressing in a host cell a plasmid expression vector, said method  
5 comprising:

introducing into said host cell said plasmid expression vector comprising a double-stranded DNA comprising a sense strand and an antisense strand, wherein said sense strand codes for a catalytic domain, which when expressed as RNA cleaves a mRNA sequence transcribed from a target nucleic acid, and binding sequences flanking said catalytic domain  
10 for binding said RNA to said mRNA, and wherein a means for determining directionality of expression is included in said double-stranded DNA, whereby said plasmid expression vector is expressed in said host cells.

41. The method according to Claim 40, wherein said plasmid expression vector is  
15 expressed in said host cell(s) without an intervening bacterial cloning step.

42. The method according to Claim 40, wherein said plasmid expression vector is a retrovirus expression vector.

43. The method according to Claim 40, wherein said plasmid expression vector is an  
20 adeno-associated virus expression vector.

44. The method according to Claim 40, wherein said plasmid expression vector is contacted with gyrase.  
25

45. A method for construction of a ribozyme vector, said method comprising:  
inserting a double-stranded DNA into a linearized delivery vector, wherein said double-stranded DNA comprises a sense strand and an antisense strand, wherein said sense strand codes for a catalytic domain which when expressed as RNA cleaves a mRNA sequence  
30 transcribed from a target nucleic acid, and binding sequences flanking said catalytic domain for binding said RNA to said mRNA.

46. The method according to Claim 45, wherein said double-stranded DNA is formed by contacting a first oligonucleotide with a complementary second oligonucleotide.

47. The method according to Claim 46, wherein a means for determining directionality of expression is included in said double-stranded DNA.

5        48. The method according to Claim 47, wherein said means for determining directionality of expression comprises a different non blunt-ended restriction enzyme site at each end of said double-stranded DNA.

49. The method according to Claim 45, wherein said double-stranded DNA is formed  
10 by annealing a first oligonucleotide, a second oligonucleotide, and a third oligonucleotide, wherein said second oligonucleotide is complementary to nucleotides at the 5' end of said first oligonucleotide, wherein said second oligonucleotide further comprises excess nucleotides extending beyond the 5' end of said first oligonucleotide, wherein said third oligonucleotide is complementary to nucleotides at the 3' end of said first oligonucleotide, and wherein said  
15 third oligonucleotide contains excess nucleotides that extend beyond the 3' end of said first oligonucleotide.

50. The method according to Claim 49, wherein said excess nucleotides are complementary to and base pair with the ends of said linearized delivery vector.  
20

51. The method according to Claim 49, wherein said ribozyme vector is treated with a DNA polymerase.

52. The method according to Claim 51, wherein said DNA polymerase is a cellular  
25 DNA polymerase.

53. The method according to Claim 51, wherein said DNA polymerase is a Taq DNA polymerase.

30        54. The method according to Claim 51, wherein said DNA polymerase is Klenow.

55. A method for construction of a ribozyme vector, said method comprising:

contacting a single-stranded oligonucleotide with a linearized delivery vector wherein said single-stranded oligonucleotide or a strand that is complementary to said single-stranded oligonucleotide encodes a transcription product that is a ribozyme, wherein said single-stranded oligonucleotide is complementary to one end of said delivery vector and base pairs  
5 with said delivery vector, and wherein said strand that is complementary to said single-stranded oligonucleotide is formed with a DNA polymerase.

56. The method according to Claim 55, wherein said DNA polymerase is Klenow.

10

57. The method according Claim 43 or Claim 55, wherein said ribozyme vector further comprises regulatory elements for expression.

Figure 1A

Synthetic Oligonucleotide DNA Family Encoding  
Anti-Green Fluorescent Protein Ribozymes

1)	5'	-CCAGCTC	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACCAGGA	-3'
	3'	-GGTCGAG	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGGTCCT	-5'
2)	5'	-GGCCGTT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACGTCGC	-3'
	3'	-CCGGCAA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGCAGCG	-5'
3)	5'	-CTCGCCG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACACGCT	-3'
	3'	-GAGCGGC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGTGCGA	-5'
4)	5'	-GCAGATG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACTTCAG	-3'
	3'	-CGTCTAC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGAAGTC	-5'
5)	5'	-TGGTCAC	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AGGTTGG	-3'
	3'	-ACCAAGT	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TCCCACC	-5'
6)	5'	-AGCGGCT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AGGCACT	-3'
	3'	-TCGCCGA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TCCGTGA	-5'
7)	5'	-CATGGCG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACTTGAA	-3'
	3'	-GTACCGC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGAACCT	-5'
8)	5'	-GCTCCTG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACGTAGC	-3'
	3'	-CGAGGAC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGCATCG	-5'
9)	5'	-CGTCCCT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AAGAAGA	-3'
	3'	-GCAGGAA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TTCTTCT	-5'

Figure 1B

Synthetic Oligonucleotide DNA Family Encoding  
Anti-Green Fluorescent Protein Ribozymes

10)	5'	-CGCCCTC	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AAC	TTC	A-3'
	3'	-GCGGGAG	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TTG	AAG	T-5'
11)	5'	-TGCGGTT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACC	AGG	G-3'
	3'	-ACGCCAA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TGG	TCC	C-5'
12)	5'	-CCTCCTT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AAG	TCA	A-3'
	3'	-GGAGGAA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TTG	AGG	T-5'
13)	5'	-GTAGTTG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACT	CCG	A-3'
	3'	-CATCAAC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TG	AGG	T-5'
14)	5'	-TGATATA	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACG	TTG	T-3'
	3'	-ACTATAT	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TG	CA	A-5'
15)	5'	-GGATCTT	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AAG	TTC	A-3'
	3'	-CCTAGAA	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TTG	AAG	T-5'
16)	5'	-GGTCGGC	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	AGC	TGC	A-3'
	3'	-CCAGCCG	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TCG	ACG	T-5'
17)	5'	-GCAGCAG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACG	GGG	C-3'
	3'	-CGTCGTC	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TG	CCCC	G-5'
18)	5'	-CAGGGCG	C	TGA	TGA	GTC	CGT	GAG	GAC	GAA	ACT	GGG	T-3'
	3'	-GTCCCCG	G	ACT	ACT	CAG	GCA	CTC	CTG	CTT	TG	ACCC	A-5'



Figure 1C

Synthetic Oligonucleotide DNA Family Encoding  
Anti-Green Fluorescent Protein Ribozymes

- |     |    |  |            |
|-----|----|--|------------|
| 19) | 5' | -CCAGCAG C TGA TGA GTC CGT GAG GAC GAA | ACCATGT-3' |
|     | 3' | -GGTCGTC G ACT ACT CAG GCA CTC CTG CTT | TGGTACA-5' |
| 20) | 5' | -CCATGCC C TGA TGA GTC CGT GAG GAC GAA | AGAGTGA-3' |
|     | 3' | -GGTACGG G ACT ACT CAG GCA CTC CTG CTT | TCTCACT-5' |

A.

pGEM-Sca/Pvu      AGT ACT TTC GGC ATC ACT GCC TCA TCA GCA GCT GGG  
pGEM-oligo1/3      AAG CTT TTC GGC ATC ACT GCC TCA TCA GGA ATT CGG

B.

pGEMEX-Sma/Kpn      GCC AGT ACC GAT GGA GGC AGT GAT GCC GAA CCC GGG GGC CCG  
CGG TCA TGG GCT ACT CCG TCA CTA CGG CTT GGG CCC CCG GGC

pGEMEX-oligo2/3      CCG AAT TCC TGA TGA GGC AGT GAT GCC GAA AAG CTT GGC CCG  
GGC TTA AGG ACT ACT CCG TCA CTA CGG CTT TTC GAA CCG GGC

Fig. 2

Clone 1: CGG GCC AAG CTT TTC GGC ATC ACT GCC TCA TCA GGA ATT CGG CCG CAT GCA  
Clone 2: CGG GCC AAG CTT TTC GGC ATC ACT GCC TCA TCA GGA ATT CGG CCG CAT GCA  
Clone 3: CGG GCC AAG CTT TTC GGC ATC ACT GCC TCA TCA GGA ATT CGG CCG CAT GCA  
pGEMEX: CGG GCC CTC TAG ATG

Fig. 3

Clone 1:	GGC	CTG	CAA	AGC	TTT	TCG	GCA	TCA	CTG	CCT	CAT	CAG	GAA	TTC	GGC	CTG	CAT	AAG	CTT
Clone 2:	GGC	TG	CAA	AGC	TTT	TCG	GCA	TCA	CTG	CCT	CAT	CAG	GAA	TTC	GGC	CTG	CAT	AAG	CTT
Clone 3:	GGC	CTG	CAA	AGC	TTT	TCG	GCA	TCA	CTG	CCT	CAT	CAG	GAA	TTC	GGC	CTG	CAT	AAG	CTT
pGEMEX:	GGC	CGC	A													TG	CAT	AAG	CTT

Fig. 4

### DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC ACIDS** the specification of which X is attached hereto was filed on December 18, 1998 as International Application No. PCT/US98/27942.

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

#### Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
IN	2828/MAS/98	December 18, 1998	Yes

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:




Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/995,234	December 19, 1997	Pending
09/200,013	November 25, 1998	Pending
09/199,522	November 25, 1998	Pending
PCT/US98/27942	December 18, 1998	N/A

Full Name of Inventor 1:	Full Name <b>James G. Keck</b>		
Residence & Citizenship:	City: <b>Redwood City</b>	State/Foreign Country <b>California</b>	Country of Citizenship <b>US</b>
Post Office Address:	Post Office Address <b>617 Harbor Colony Court, Redwood City, CA 94065</b>		
Full Name of Inventor 2:	Full Name <b>Molony, Jocelyn M.</b>		
Residence & Citizenship:	City: <b>Castro Valley</b>	State/Foreign Country <b>California</b>	Country of Citizenship <b>US</b>
Post Office Address:	Post Office Address <b>18691 West Cavendish Drive, Castro Valley, CA 94552</b>		
Full Name of Inventor 3:	Full Name <b>Kuo, Sophia S.</b>		
Residence & Citizenship:	City: <b>San Francisco</b>	State/Foreign Country: <b>CA</b>	Country of Citizenship <b>US</b>
Post Office Address:	Post Office Address <b>59 Surrey Street #3, San Francisco, CA 94131</b>		

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
		
<b>James G. Keck</b>	<b>Jocelyn M. Molony</b>	<b>Sophia S. Kuo</b>
Date	Date	Date <b>7/31/00</b>

### DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NON-BACTERIAL CLONING IN DELIVERY AND EXPRESSION OF NUCLEIC ACIDS** the specification of which X is attached hereto was filed on December 18, 1998 as International Application No. PCT/US98/27942.

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

#### Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
IN	2828/MAS/98	December 18, 1998	Yes

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:




Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/995,234	December 19, 1997	Pending
09/200,013	November 25, 1998	Pending
09/199,522	November 25, 1998	Pending
PCT/US98/27942	December 18, 1998	N/A

Full Name of Inventor 1	Full Name. <b>James G. Keck</b>		
Residence & Citizenship:	City <b>Redwood City</b> <i>CA</i>	State/Foreign Country <b>California</b>	Country of Citizenship <b>US</b>
Post Office Address:	Post Office Address <b>617 Harbor Colony Court, Redwood City, CA 94065</b>		
Full Name of Inventor 2	Full Name. <b>Molony, Jocelyn M.</b>		
Residence & Citizenship:	City <b>Castro Valley</b> <i>CA</i>	State/Foreign Country <b>California</b>	Country of Citizenship <b>US</b>
Post Office Address:	Post Office Address. <b>18691 West Cavendish Drive, Castro Valley, CA 94552</b>		
Full Name of Inventor 3	Full Name <b>Kuo, Sophia S.</b>		
Residence & Citizenship:	City: <b>San Francisco</b> <i>CA</i>	State/Foreign Country <b>CA</b>	Country of Citizenship. <b>US</b>
Post Office Address:	Post Office Address. <b>59 Surrey Street #3, San Francisco, CA 94131</b>		

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  <b>James G. Keck</b>	Signature of Inventor 2  <b>Jocelyn M. Molony</b>	Signature of Inventor 3  <b>Sophia S. Kuo</b>
Date <b>8-4-00</b>	Date <b>24 JULY 2000</b>	Date



1  
SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Keck, James G; Molony, Jocelyn M; Kuo, Sophia S

(ii) TITLE OF INVENTION: Non-Bacterial Cloning in Delivery and Expression of Nucleic Acids

(iii) NUMBER OF SEQUENCES: 46

## (iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Rae-Venter Law Group, P.C.
- (B) STREET: P.O. Box 60039
- (C) CITY: Palo Alto
- (D) STATE: California
- (E) COUNTRY: USA
- (F) ZIP: 94306-0039

## (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE: 18-DEC-1998
- (C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Rae-Venter, Barbara
- (B) REGISTRATION NUMBER: 32,750
- (C) REFERENCE/DOCKET NUMBER: STBI.001.01US

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (650) 328-4400
- (B) TELEFAX: (650) 328-4477

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCAGCTCCTG ATGAGTCCGT GAGGACGAAA CCAGGA

36

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGCCGTTCTG ATGAGTCCGT GAGGACGAAA CGTCGC

36

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTCGCCGCTG ATGAGTCCGT GAGGACGAAA CACGCT

36

(2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCAGATGCTG ATGAGTCCGT GAGGACGAAA CTTCAG

36

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TGGTCACCTG ATGAGTCCGT GAGGACGAAA GGGTGG

36

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGCGGCTCTG ATGAGTCCGT GAGGACGAAA GGCAC T

36

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CATGGCGCTG ATGAGTCCGT GAGGACGAAA CTTGAA

36

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCTCCTGCTG ATGAGTCCGT GAGGACGAAA CGTAGC

36

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGTCCTTCTG ATGAGTCCGT GAGGACGAAA AGAAGA

36

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGCCCTCCTG ATGAGTCCGT GAGGACGAAA ACTTCA

36

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGCGGTTCTG ATGAGTCCGT GAGGACGAAA CCAGGG

36

(2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCTCCTTCTG ATGAGTCCGT GAGGACGAAA AGTCGA

36

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTAGTTGCTG ATGAGTCCGT GAGGACGAAA CTCCAG

36

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGATATACTG ATGAGTCCGT GAGGACGAAA CGTTGT

36

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGATCTTCTG ATGAGTCCGT GAGGACGAAA AGTTCA

36

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGTCGGCCTG ATGAGTCCGT GAGGACGAAA GCTGCA

36

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCAGCAGCTG ATGAGTCCGT GAGGACGAAA CGGGGC

36

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CAGGGCGCTG ATGAGTCCGT GAGGACGAAA CTGGGT

36

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CCAGCAGCTG ATGAGTCCGT GAGGACGAAA CCATGT

36

(2) INFORMATION FOR SEQ ID NO:20:



## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCATGCCCTG ATGAGTCCGT GAGGACGAAA GAGTGA

36

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGCTTCCAGC TCCTGATGAG TCCGTGAGGA CGAAACCAGG AAT

43

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CGATTCCTGG TTTCGTCCTC ACGGACTCAT CAGGAGCTGG A

41

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGCCGAATTC CTGATGAGGC AGTGATGCCG AAAAGCTTTG CA

42

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GGCCGAATTC CTGATGAGGC AGTGATGCCG AAAAGCTTGG CC

42

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAGCTTTTTCG GCATCACTGC CTCATCAGGA ATTG

34

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TACTCAAGCT ATGCAAGTAC TTTCGGCATC ACTGCCTCAT C

41

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATCACTAGTG CGGCCAGCT GCTGATGAGG CAGTGATGCC G

41

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGAGGGATCC GGGCCCCCGG GTTCGGCATC ACTGCCTCAT C

41

- (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 43 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CTTATGCATG CGGCCGGTAC CCTGATGAGG CAGTGTGATG CCG

43

- (2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TTGGGCCCCGA CGTCGCATG

19

- (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GAATTGGGCC CGACGTCGC

19

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TGTGAGCGGA TAACAATTTC ACAC

24

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GAATACTCAA GCTTATGCAT G

21 -

## (2) INFORMATION FOR SEQ ID NO:34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GAGGTGTAG AAGTTCCGC

19

## (2) INFORMATION FOR SEQ ID NO:35:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CATCAGGAAT TCGCCGGCC

20

## (2) INFORMATION FOR SEQ ID NO:36:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GGCCTGCAAA GCTTTTCGG

19

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CATCAGGAAT TCGCCTGCA

20

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

AGTACTTTTCG GCATCACTGC CTCATCAGCA GCTGGG

36

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

AAGCTTTTTCG GCATCACTGC CTCATCAGGA ATTGGG

36

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GCCAGTACCG ATGGAGGCAG TGATGCCGAA CCGGGGGGCC CG

42

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CCGAATTCTT GATGAGGCAG TGATGCCGAA AAGCTTGGCC CG

42

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double



(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CGGGCCAAGC TTTTOGGCAT CACTGCCTCA TCAGGAATTC GGCCGCATGC A

51

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CGGGCCCTCT AGATGCGGCC GCATGCA

27

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GGCCTGCAAA GCTTTTCGGC ATCACTGCCT CATCAGGAAT TCGGCCTGCA TAAGCTT

57

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

18

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GGCTGCAAAG CTTTTCGGCA TCACTGCCTC ATCAGGAATT CGGCCTGCAT AAGCTT

56

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Plasmid DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GGCCGCATGC ATAAGCTT

18